Varlilumab
Varlilumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target CD27 antigen.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | 4 | 1 | — | — | — | 4 | ||
| Melanoma | D008545 | 3 | 3 | — | — | — | 4 | ||
| B-cell lymphoma | D016393 | 1 | 2 | — | — | — | 2 | ||
| Burkitt lymphoma | D002051 | C83.7 | 1 | 1 | — | — | — | 2 | |
| Glioblastoma | D005909 | EFO_0000515 | 1 | 2 | — | — | — | 2 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | 1 | — | — | — | 1 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | — | 1 | — | — | — | 1 | |
| Plasmablastic lymphoma | D000069293 | C83.3 | — | 1 | — | — | — | 1 | |
| Lymphomatoid granulomatosis | D008230 | C83.8 | — | 1 | — | — | — | 1 | |
| Primary effusion lymphoma | D054685 | C83.8 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 3 | — | — | — | — | 3 | ||
| Kidney diseases | D007674 | EFO_0003086 | N08 | 2 | — | — | — | — | 2 |
| Urologic neoplasms | D014571 | C64-C68 | 2 | — | — | — | — | 2 | |
| Neoplasms | D009369 | C80 | 2 | — | — | — | — | 2 | |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 2 | — | — | — | — | 2 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 2 | — | — | — | — | 2 |
| Urologic diseases | D014570 | N39.9 | 2 | — | — | — | — | 2 | |
| Neoplasms by histologic type | D009370 | 2 | — | — | — | — | 2 | ||
| Lung neoplasms | D008175 | C34.90 | 1 | — | — | — | — | 1 | |
| Triple negative breast neoplasms | D064726 | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VARLILUMAB |
| INN | varlilumab |
| Description | Varlilumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1393344-72-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3137347 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11930 |
| UNII ID | 0125DUV5XC (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CD27
CD27
Organism
Homo sapiens
Gene name
CD27
Gene synonyms
TNFRSF7
NCBI Gene ID
Protein name
CD27 antigen
Protein synonyms
CD27, CD27L receptor, T cell activation antigen S152, T-cell activation antigen CD27, T14, Tumor necrosis factor receptor superfamily member 7, tumor necrosis factor receptor superfamily, member 7
Uniprot ID
Mouse ortholog
Cd27 (21940)
CD27 antigen (P41272)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 285 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more